Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme

Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials

(2018) Paolo Pozzilli et al.   DIABETES OBESITY & METABOLISM

Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreaticβ-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes

(2016) A. Mari et al.   DIABETES OBESITY & METABOLISM

EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM

(2016) Jaime A. Davidson et al.   Endocrine Practice

Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial

(2016) Daniël H van Raalte et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials

(2016) Daisuke Yabe et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists

(2015) Sten Madsbad   DIABETES OBESITY & METABOLISM

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

(2014) Guillermo Umpierrez et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

(2014) Carol Wysham et al.   DIABETES CARE

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

(2014) Kathleen M Dungan et al.   LANCET

The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study

(2013) K. Y. Thong et al.   DIABETIC MEDICINE

Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells

(2013) Young-Sun Lee et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Relationship of baseline HbA1cand efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

(2010) R. A. DeFronzo et al.   DIABETIC MEDICINE